



# International Journal of Pharmacology

ISSN 1811-7775

**science**  
alert

**ansinet**  
Asian Network for Scientific Information



## Short Communication

# Effects of Minocycline on H<sub>2</sub>O<sub>2</sub>-induced Cell Death and Interleukin-8 Production in Human Small Airway Epithelial Cells

<sup>1,2</sup>Takahiro Sato, <sup>1,3</sup>Ayano Hirohara, <sup>1</sup>Yuki Izumi, <sup>1</sup>Takayuki Nakatomi, <sup>1,4</sup>Kuninori Iwayama, <sup>1,4</sup>Ko-Ichi Ohtaki and <sup>1</sup>Nobumasa Hayase

<sup>1</sup>Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 7-15-4-1 Maeda, Teine, Sapporo, 006-8590 Hokkaido, Japan

<sup>2</sup>Mediceo Corporation, 67-30 Kameda-honcho, Hakodate, 041-0813 Hokkaido, Japan

<sup>3</sup>Department of Dispensary, Nakajima Community Pharmacy, 10-24-2 Kita, Chu-Oh, Sapporo, 060-0010 Hokkaido, Japan

<sup>4</sup>Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University, 2-1-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan

## Abstract

**Background and Objective:** The antibiotic minocycline (MINO) is known to have anti-inflammatory activity. This study aimed to examine the effects of MINO on hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced cell death and interleukin (IL)-8 production, which have been shown to increase during inflammation, using small airway epithelial cells (SAECs). **Materials and Methods:** The SAECs were pretreated with MINO (1, 5 and 10 μM) for 24, 48 or 72 h and subsequently exposed to H<sub>2</sub>O<sub>2</sub> (100 μM) for 6 h. Cell viability was assessed using the WST-8 assay and levels of IL-8 protein were measured using an enzyme-linked immunosorbent assay (ELISA). Tukey's multiple comparison test was used for analysis of statistical significance. **Results:** Treatment of SAECs with 10 μM MINO or greater than 100 μM H<sub>2</sub>O<sub>2</sub> significantly decreased cell viability. However, pretreatment with 1 μM MINO for 24 h significantly suppressed the H<sub>2</sub>O<sub>2</sub>-induced decrease in cell viability. In addition, IL-8 production increased in the H<sub>2</sub>O<sub>2</sub> treated group as compared to the control group (not treated with H<sub>2</sub>O<sub>2</sub>), whereas IL-8 production decreased significantly following pretreatment with MINO (1, 5 or 10 μM) for 48 or 72 h. **Conclusion:** It was suggested that pretreatment of SAECs with low concentrations of MINO for 24 or 48 h has a cytoprotective effect and pretreatment for 48 or 72 h suppresses IL-8 production indicating a potential anti-inflammatory effect.

**Key words:** Minocycline, cytoprotective effect, cell death, interleukin-8, anti-inflammatory, small airway epithelial cells, immunosorbent

**Received:** November 05, 2018

**Accepted:** January 12, 2019

**Published:** April 15, 2019

**Citation:** Takahiro Sato, Ayano Hirohara, Yuki Izumi, Takayuki Nakatomi, Kuninori Iwayama, Ko-Ichi Ohtaki and Nobumasa Hayase, 2019. Effects of minocycline on H<sub>2</sub>O<sub>2</sub>-induced cell death and interleukin-8 production in human small airway epithelial cells. *Int. J. Pharmacol.*, 15: 509-514.

**Corresponding Author:** Ko-Ichi Ohtaki, Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 7-15-4-1 Maeda, Teine, Sapporo, 006-8590 Hokkaido, Japan Tel: +81 11 676 8700 Fax: +81 11 676 8666

**Copyright:** © 2019 Takahiro Sato *et al.* This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Competing Interest:** The authors have declared that no competing interest exists.

**Data Availability:** All relevant data are within the paper and its supporting information files.

## INTRODUCTION

Macrolides and tetracyclines possess anti-bacterial action and also exhibit distinct anti-inflammatory effects<sup>1-4</sup>. Chronic respiratory tract infections, in which oxidative stress is an important pathogenic factor<sup>5</sup>, are characterized by a vicious cycle of infection and inflammation, with inflammatory cytokines, mainly interleukin (IL)-8, observed to increase in bronchial epithelial cell at the infection site<sup>1,6</sup>. This precedes the development of cytotoxicity, including the death of bronchial epithelial cells<sup>1,2</sup>.

Recently, the effect of clarithromycin (CAM), a macrolide antibiotic effective for diffuse panbronchiolitis (DPB), on H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in human small airway epithelial cells (SAECs) was investigated<sup>7,8</sup>. The results revealed that long-term treatment with low-concentration CAM inhibits the production of IL-8 and enhances anti-oxidant enzyme activity, e.g., glutathione peroxidase, which protects cells from H<sub>2</sub>O<sub>2</sub>-induced oxidative toxicity. On the other hand, minocycline (MINO) is used for the treatment of mycoplasma and chlamydia pneumonia, which are classified as diffuse lung diseases<sup>9</sup> like DPB. This therapeutic effect may involve anti-inflammatory actions other than the antibacterial activity possessed by MINO. That is, MINO has been found to have multiple non-antibacterial biological activities that are beneficial in experimental models of various diseases, including autoimmune diseases such as dermatitis, rheumatoid arthritis and inflammatory bowel disease<sup>3,4</sup>. The MINO also produces a neuroprotective effect<sup>10,11</sup> that may ameliorate conditions such as ischemia, traumatic brain injury and neuropathic pain as well as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, spinal cord and its effects have been confirmed in experimental models of several neurodegenerative diseases<sup>3,4</sup>.

Based on these findings, it is possible that MINO may have the same effect as CAM against chronic inflammatory airway diseases. However, there are no reports describing the direct effects of MINO on H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in bronchial epithelial cells<sup>7,8</sup>. The purpose of this study was to examine the inhibitory effects of MINO on H<sub>2</sub>O<sub>2</sub>-induced cell death and IL-8 production in SAECs under the same conditions as long-term treatment of CAM at low concentrations previously demonstrated to show the cytoprotective effects on SAECs. Although it is not possible to directly translate a pharmacological effect in cells to treatment efficacy in clinical practice, the present study presented possible evidence that

MINO therapy is effective against chronic inflammatory airway diseases through the inhibitions of cell death and IL-8 release in bronchial epithelial cells.

## MATERIALS AND METHODS

The cultured cell study was conducted at the Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan. The total period of this research was 7 months, from September, 2017 to March, 2018.

**Materials:** The MINO hydrochloride, H<sub>2</sub>O<sub>2</sub> (30%) and the WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) assay system were purchased from Wako Pure Chemical Industries, Ltd., (Osaka, Japan). A human IL-8 enzyme-linked immunosorbent assay (ELISA) kit was purchased from Bender Med Systems (Vienna, Austria). All other chemicals used in this experiment were of research grade.

**Cell culture and drug treatments:** Cell culture and treatments were according to methods described previously<sup>7,8</sup>. Briefly, a normal human small airway epithelial cell line (SAECs) and culture media were purchased from Lonza (Walkersville, MD, USA). Cells were seeded in 75 cm<sup>2</sup> filter vent flasks (Corning, NY, USA) and were grown to 80% confluence (3 × 10<sup>6</sup> cells/well) for each experimental condition at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air. Cells were cultured in the presence or absence of MINO (1, 5 or 10 μM) for 24-72 h and were then stimulated with H<sub>2</sub>O<sub>2</sub> (100 μM) for an additional 6 h. Pre-treatments with MINO were carried out with a different set of cells for each concentration and treatment duration. For stimulation of the cells with H<sub>2</sub>O<sub>2</sub>, the medium was changed to small airway basal medium (SABM) containing no supplements<sup>12</sup>.

**Cell viability:** Cell viability was assessed using the cell counting kit-8 assay<sup>13</sup>, WST-8. After treatment with MINO and H<sub>2</sub>O<sub>2</sub>, the SAEC medium was changed to SABM containing 10% WST-8 solution and the cells were incubated at 37°C for 2 h. Viable cells convert the WST-8 solution to an orange-colored formazan product with an absorbance at 450 nm. The optical density (OD) of the culture medium was measured at 450 nm with a spectrophotometric microliter plate reader (Bio-Rad, Hercules, CA, USA). The cell proliferation and viability were expressed as the ratio (%) of surviving cells to H<sub>2</sub>O<sub>2</sub> untreated cells.

**IL-8 measurement:** After the treatments with MINO and H<sub>2</sub>O<sub>2</sub>, the culture media supernatants were collected and centrifuged to remove cell debris (12,000×g for 10 min). The IL-8 protein levels in the culture supernatants were analyzed using ELISA according to the manufacturer's instructions. Briefly, experimental samples were added into individual wells coated with human monoclonal anti-body specific for IL-8 and incubated for 3 h at room temperature. After 6 washes with phosphate-buffered saline (PBS) containing 0.1% Tween 20 to remove unbound protein, tetramethyl-benzidine was added to each well and incubated for 10 min at room temperature. The reaction was terminated by the addition of 1 M phosphoric acid. The color generated in each sample was determined by OD measurement at 450 nm using a spectrophotometric microliter plate reader. The IL-8 protein levels of unknown samples were calculated using a standard curve.

**Statistical analysis:** All data were expressed as Means±SD. Statistical analysis was performed using one-way analysis of variance (ANOVA) and differences, which were estimated by Tukey's multiple comparison test after the Goodness of fit test and Bartlett's test were considered to be statistically significant at p<0.05.

## RESULTS

**Effects of MINO and H<sub>2</sub>O<sub>2</sub> on SAEC cell growth:** Treatment of SAECs with 1 or 5 μM MINO for up to 72 h produced no significant change in cell viability. However, at a high concentration (10 μM), cell viability decreased significantly (p<0.01) compared to the control group indicating the cytotoxicity of MINO (Table 1). On the other hand, following H<sub>2</sub>O<sub>2</sub> treatment (100, 300 and 500 μM) for 6 h, cell viability decreased in a concentration-dependent

manner to 77.6±10.4, 65.9±6.4 and 26.4±1.5%, respectively. Furthermore, treatment with H<sub>2</sub>O<sub>2</sub> for 24 h resulted in a stronger reduction in cell viability at 300 and 500 μM (Table 2).

**Effect of MINO pre-treatment on H<sub>2</sub>O<sub>2</sub>-induced cell death in SAECs:** Pre-treatment of SAECs with 1 μM MINO for 24 or 48 h prior to H<sub>2</sub>O<sub>2</sub> (100 μM) treatment significantly (p<0.01 or p<0.05) suppressed the H<sub>2</sub>O<sub>2</sub>-induced decrease in cell viability compared to 100 μM H<sub>2</sub>O<sub>2</sub> treatment alone. Additionally, pre-treatment with 5 μM MINO for 24 h significantly suppressed the H<sub>2</sub>O<sub>2</sub>-induced decrease in cell viability (p<0.01). However, at a high concentration (10 μM) of MINO, the H<sub>2</sub>O<sub>2</sub>-induced decrease in cell viability was not suppressed at any time point assayed (Table 3).

**Effect of MINO pre-treatment on H<sub>2</sub>O<sub>2</sub>-induced IL-8 protein release in SAECs:** The exposure of SAECs to H<sub>2</sub>O<sub>2</sub> (100 μM) caused an increase in supernatant IL-8 levels (significantly increased at 48 h) compared to the control group. Pre-treatments with 1 or 5 μM MINO for 48 or 72 h and with 10 μM MINO for up to 72 h prior to H<sub>2</sub>O<sub>2</sub> treatment significantly (p<0.01 or p<0.05) decreased H<sub>2</sub>O<sub>2</sub>-induced IL-8 protein release compared to H<sub>2</sub>O<sub>2</sub> treatment alone (Fig. 1).

Table 1: Effect of MINO on SAEC cell growth

Groups	Cell viability (%)		
	MINO treatment time (h)		
	24	48	72
Control cells	100.0±9.8	100.0± 6.8	100.0± 9.0
1 μM MINO	104.9± 8.6	95.4± 6.0	105.2± 8.6
5 μM MINO	85.4± 7.7	86.9± 6.1	91.2± 7.1
10 μM MINO	67.9± 8.5**	70.2±9.0**	69.7± 5.5**

Cell viabilities of the MINO untreated group (control cells) at each treatment time are expressed as 100%, data are expressed as Means±SD of six independent experiments, \*\*p<0.01 vs. control cells




Fig. 1: Effect of MINO pretreatment on IL-8 production

Data are expressed as Means±SD of three independent experiments, \*p<0.05, \*\*p<0.01 vs. control cells, #p<0.05, ##p<0.01 vs. cells stimulated with H<sub>2</sub>O<sub>2</sub> alone

Table 2: Effect of H<sub>2</sub>O<sub>2</sub> on SAEC cell growth

Groups	Cell viability (%)	
	H <sub>2</sub> O <sub>2</sub> treatment time (h)	
	6	24
Control cells	100.0±12.4	100.0±10.8
100 µM H <sub>2</sub> O <sub>2</sub>	77.6±10.4**	76.2±3.5**
300 µM H <sub>2</sub> O <sub>2</sub>	65.9±6.4**	57.7±5.3**
500 µM H <sub>2</sub> O <sub>2</sub>	26.4±1.5**	21.4±0.8**

Cell viabilities of the H<sub>2</sub>O<sub>2</sub> untreated group (control cells) at each treatment time are expressed as 100%, data are expressed as Means±SD of six independent experiments, \*\*p<0.01 vs. control cells

Table 3: Effect of MINO pre-treatment on H<sub>2</sub>O<sub>2</sub>-induced cell death in SAECs

Treatment groups	Cell viability (%)		
	MINO pre-treatment time (h)		
	24	48	72
Control cells	100.0±8.5	100.0±7.6	100.0±11.0
100 µM H <sub>2</sub> O <sub>2</sub> alone	62.5±2.3**	77.1±5.6**	81.3±3.6*
100 µM H <sub>2</sub> O <sub>2</sub> +1 µM MINO	94.6±9.8#	94.2±6.8#	91.4±3.5
100 µM H <sub>2</sub> O <sub>2</sub> +5 µM MINO	84.3±9.6#	77.7±5.9**	85.3±5.3
100 µM H <sub>2</sub> O <sub>2</sub> +10 µM MINO	64.7±5.3**	66.1±8.4**	70.4±9.0**

Cell viabilities of the MINO and H<sub>2</sub>O<sub>2</sub> untreated group (control cells) at each pre-treatment time are expressed as 100%, data are expressed as Means±SD of six independent experiments, \*p<0.05, \*\*p<0.01 vs. control cells, #p<0.05, ##p<0.01 vs. cells stimulated with H<sub>2</sub>O<sub>2</sub> alone

## DISCUSSION

The results of this work showed that pre-treatment of SAECs with low concentrations (1 or 5 µM) of MINO for 24 or 48 h significantly suppressed the H<sub>2</sub>O<sub>2</sub>-induced decrease in cell viability and pre-treatment for 48 or 72 h significantly decreased IL-8 protein release.

The MINO concentrations of 1, 5 and 10 µM used in this study were deemed reasonable because an adult taking 200 mg of MINO per day would exhibit blood levels of approximately<sup>14</sup> 1-5 µM. In addition, a 2-4 fold higher concentration (2-20 µM) was detected in human sputum and bronchial secretion fluid<sup>15</sup>. However, in a study examining the anti-tumor effect of MINO on mouse epithelial ovarian cancer cells<sup>16</sup> and human leukemia cells<sup>17</sup>, MINO decreased cell viability, with IC<sub>50</sub> values of 10-30 µg mL<sup>-1</sup> (about 22-66 µM). Therefore, it was suggested that the cytotoxic concentration of MINO obtained in this study was lower than those reported values due to differences in experimental conditions, such as the cell type used and the evaluation method of cell viability. On the other hand, during inflammatory conditions in the lower respiratory tract, neutrophil-derived H<sub>2</sub>O<sub>2</sub> in the respiratory tract viscous fluid is reported to reach a concentration of 50 µM<sup>18</sup>. Since H<sub>2</sub>O<sub>2</sub> is also produced directly from bronchial epithelial cells following stimulation with

pollutants such as bacteria and lipopolysaccharide<sup>19</sup>, it was proposed that the H<sub>2</sub>O<sub>2</sub> concentration (100 µM) used in this study reflects conditions observed during chronic inflammatory airway diseases.

Inflammation is the immune system's response to harmful stimuli such as pathogens, damaged cells, toxic compounds, reactive oxygen species or radiation<sup>20</sup> and uncontrolled inflammation finally leads to a loss of tissue function or cell viability at the tissue or cell level<sup>21</sup>. It has been shown that MINO causes a concentration-dependent protective effect on cell viability after oxidative stress<sup>22,23</sup>. Also in SAECs of this study, MINO suppressed cell death due to H<sub>2</sub>O<sub>2</sub> (100 µM)-induced oxidative stress at low concentrations (1 and 5 µM). However, since cytotoxicity was observed at 10 µM MINO, the decrease in cell viability induced by H<sub>2</sub>O<sub>2</sub> may be further decreased depending on the MINO concentration in excess of the toxic threshold. Accordingly, when the MINO pre-treatment time is prolonged, evidence of cytotoxicity appears at low MINO concentrations, notably at 5 µM and the inhibitory effect of MINO on H<sub>2</sub>O<sub>2</sub>-induced cell death may be attenuated.

In regards to cell viability, the greatest effect was obtained by pretreatment with MINO for 24 h; however, the effect on IL-8 production released during the inflammatory process as an inflammatory cytokine<sup>1,6,24</sup> was inconsistent with this result. It was thought that inflammatory cytokines other than IL-8 might be involved in the mechanism of MINO's cytoprotective effect. Because MINO suppresses the activation of nuclear transcription<sup>25</sup> factor (NF)-κB, it is possible that the production of IL-1, IL-6 or tumor necrosis factor (TNF)-α induced by NF-κB is also suppressed. In this study, IL-8, which is considered the principal inflammatory mediator<sup>1,6</sup> was used as an index; however, the expression pattern of each cytokine varies depending on the MINO and H<sub>2</sub>O<sub>2</sub> treatment conditions<sup>25,26</sup>. Therefore, it is possible that there will be a difference in the relationship between the production of respective cytokines and cell viability. Nevertheless, pretreatment with 10 µM MINO significantly reduced the production of IL-8 at all time points assayed. The reason for this observation may be that the cytotoxicity from 10 µM MINO reduced the number of IL-8-producing SAECs. It is known that reactive oxygen species such as H<sub>2</sub>O<sub>2</sub> regulate the DNA binding activity of nuclear transcription factors such as NF-κB, altering gene expression and activating a number of major signaling pathways leading to cell death<sup>27</sup>.

Therefore, compounds with antioxidant activity are considered to be effective for the inhibition of cytotoxicity and cell death caused by oxidative toxicity. Similar to α-tocopherol, MINO contains a multi-substituted phenol

ring in its chemical structure and shows reactive oxygen species scavenging ability<sup>23</sup>. It was suggested that the direct anti-oxidant activity of MINO contributes, at least in part, to the suppression of H<sub>2</sub>O<sub>2</sub>-induced cell death and IL-8 production in SAECS.

### CONCLUSION

This study showed that pre-treatment of SAECS with low concentrations (1 or 5 µM) of MINO for 24 or 48 h suppresses cell death after H<sub>2</sub>O<sub>2</sub> treatment (100 µM) and pre-treatment for 48 or 72 h inhibits IL-8 release. Therefore, it was expected that MINO may also exhibit cytoprotective and anti-inflammatory effects in bronchial epithelial cells.

### SIGNIFICANCE STATEMENT

This study revealed possible cytoprotective effects on H<sub>2</sub>O<sub>2</sub>-induced cell death and IL-8 protein release in SAECS after pretreatment with MINO, which can be beneficial for the treatment of chronic airway inflammatory diseases. This study will assist researchers in uncovering a critical area of inflammatory-mediated bronchial epithelial cell death through oxidative stress that has previously been difficult to assess. Previous studies have not explored anti-inflammatory activities after pretreatment with MINO on chronic airway inflammatory diseases but instead focused on dermatitis, rheumatoid arthritis, central nerve system (CNS) diseases, neuropathic pain, ischemia, inflammatory bowel disease and cancer. Thus, new therapeutic regimens that effectively combat chronic airway inflammatory diseases may be developed.

### REFERENCES

1. Khair, O.A., J.L. Devalia, M.M. Abdelaziz, R.J. Sapsford and R.J. Davies, 1995. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur. Respir. J., 8: 1451-1457.
2. Pukhalsky, A.L., G.V. Shmarina, N.I. Kapranov, S.N. Kokarovtseva, D. Pukhalskaya and N.J. Kashirskaja, 2004. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm., 13: 111-117.
3. Garrido-Mesa, N., A. Zarzuelo and J. Galvez, 2013. Minocycline: Far beyond an antibiotic. Br. J. Pharmacol., 169: 337-352.
4. Garrido-Mesa, N., A. Zarzuelo and J. Galvez, 2013. What is behind the non-antibiotic properties of minocycline? Pharmacol. Res., 67: 18-30.
5. Holguin, F., 2013. Oxidative stress in airway diseases. Ann. Am. Thorac. Soc., 10: 150-157.
6. Hou, Y., J. An, X.R. Hu, B.B. Sun and J. Lin *et al.*, 2009. Ghrelin inhibits interleukin-8 production induced by hydrogen peroxide in A549 cells via NF-κB pathway. Int. Immunopharmacol., 9: 120-126.
7. Iwayama, K., A. Kusakabe, K. Ohtsu, T. Nawano and R. Tatsunami *et al.*, 2017. Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. BMC Pharmacol. Toxicol., Vol. 18. 10.1186/s40360-017-0119-8.
8. Iwayama, K., J. Kimura, A. Mishima, A. Kusakabe, K.I. Ohtaki, Y. Tampo and N. Hayase, 2018. Low concentrations of clarithromycin upregulate cellular antioxidant enzymes and phosphorylation of extracellular signal-regulated kinase in human small airway epithelial cells. J. Pharm. Health Care Sci., Vol. 4. 10.1186/s40780-018-0120-4.
9. Bajantri, B., S. Venkatram and G. Diaz-Fuentes, 2018. *Mycoplasma pneumoniae*: A potentially severe infection. J. Clin. Med. Res., 10: 535-544.
10. Morimoto, N., M. Shimazawa, T. Amashima, H. Nagai and H. Hara, 2005. Minocycline inhibits oxidative stress and decreases *in vitro* and *in vivo* ischemic neuronal damage. Brain. Res., 1044: 8-15.
11. Jordan, J., F.J. Fernandez-Gomez, M. Ramos, I. Ikuta, N. Aguirre and M.F. Galindo, 2007. Minocycline and cytoprotection: Shedding new light on a shadowy controversy. Curr. Drug Deliv., 4: 225-231.
12. Parthasarathy, S., J. Barnett and L.G. Fong, 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta (BBA)-Lipids Lipid Metab., 1044: 275-283.
13. Reilly, C.A., J.L. Taylor, D.L. Lanza, B.A. Carr, D.J. Crouch and G.S. Yost, 2003. Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors. Toxicol. Sci., 73: 170-181.
14. Kelly, R.G. and L.A. Kanegis, 1967. Metabolism and tissue distribution of radioisotopically labeled minocycline. Toxicol. Applied Pharmacol., 11: 171-183.
15. Naline, E., M. Sanceaume, L. Toty, H. Bakdach, M. Pays and C. Advenier, 1991. Penetration of minocycline into lung tissues. Br. J. Clin. Pharmacol., 32: 402-404.
16. Pourgholami, M.H., A.H. Mekawy, S. Badar and D.L. Morris, 2012. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol. Oncol., 125: 433-440.
17. Fares, M., M. Abedi-Valugerdi, M. Hassan and Z. Potacova, 2015. DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line. Biochem. Biophys. Res. Commun., 463: 268-274.

18. Test, S.T. and S.J. Weiss, 1984. Quantitative and temporal characterization of the extracellular H<sub>2</sub>O<sub>2</sub> pool generated by human neutrophils. *J. Biol. Chem.*, 259: 399-405.
19. Rada, B. and T.L. Leto, 2010. Characterization of hydrogen peroxide production by Duox in bronchial epithelial cells exposed to *Pseudomonas aeruginosa*. *FEBS Lett.*, 584: 917-922.
20. Medzhitov, R., 2010. Inflammation 2010: New adventures of an old flame. *Cell*, 140: 771-776.
21. Chen, L., H. Deng, H. Cui, J. Fang and Z. Zuo *et al.*, 2017. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9: 7204-7218.
22. Song, X., A. Xu, W. Pan, B. Wallin and R. Kivlin *et al.*, 2008. Minocycline protects melanocytes against H<sub>2</sub>O<sub>2</sub>-induced cell death via JNK and p38 MAPK pathways. *Int. J. Mol. Med.*, 22: 9-16.
23. Kraus, R.L., R. Pasieczny, K. Lariosa Willingham, M.S. Turner, A. Jiang and J.W. Trauger, 2005. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical scavenging activity. *J. Neurochemistry*, 94: 819-827.
24. Jabbour, H.N., K.J. Sales, R.D. Catalano and J.E. Norman, 2009. Inflammatory pathways in female reproductive health and disease. *Reproduction*, 138: 903-919.
25. Sun, J., H. Shigemitsu, Y. Tanaka, T. Yamauchi, T. Ueda and H. Iwasaki, 2015. Tetracyclines downregulate the production of LPS-induced cytokines and chemokines in THP-1 cells via ERK, p38 and nuclear factor- $\kappa$ B signaling pathways. *Biochem. Biophys. Rep.*, 4: 397-404.
26. Oliveira-Marques, V., H.S. Marinho, L. Cyrne and F. Antunes, 2009. Role of hydrogen peroxide in NF- $\kappa$ B activation: From inducer to modulator. *Antioxid. Redox Signal.*, 11: 2223-2243.
27. Martindale, J.L. and N.J. Holbrook, 2002. Cellular response to oxidative stress: Signaling for suicide and survival. *J. Cell. Physiol.*, 192: 1-15.